SNAI1 and prostate cancer: As sumoylation inhibitors are currently being tested to combat breast cancer tumorigenesis [55], it would be interesting to target Snail1 sumoylation to inhibit migration and invasion in prostate cancer, as we in this report identify sumoylated Snail1 as a crucial modulator of the EMT program in androgen independent aggressive prostate cancer cells and also in the highly invasive breast cancer (MDA-MB-231) and lung cancer cells (A549).